EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quality of amoxicillin/clavulanic acid oral formulations for intended veterinary use in the UK, Malaysia, Serbia and Thailand

L Pelligand iD, D Baker, A Sivagurunathan, Z Kovačević, N Suemanotham, J L Stair, M Scott, F Liu, S W Page, L Guardabassi, P V Steagall iD, Therapeutic Guidelines Group of the World Small Animal Veterinary Association

Journal of Small Animal Practice · 2023

DOI: 10.1111/jsap.13648 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Small Animal Practice, 2023. Verfasst von L Pelligand und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Services and Sciences and Department of Comparative Biomedical Sciences, Royal Veterinary College, Hatfield, UK. Hauptthemen laut MEDLINE: Amoxicillin-Potassium Clavulanate Combination, Anti-Infective Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Amoxicillin/clavulanate is the most commonly used oral antimicrobial drug in companion animals. The objective of the study was to detect types and frequency of deficits in the quality of veterinary oral formulations of amoxicillin/clavulanate in various countries. Materials and Methods In a prospective study with purposive sampling, amoxicillin/clavulanate tablet formulations for canine use were collected in four countries (wholesalers or veterinary practice) and shipped to a central bioanalytical laboratory. Twenty‐four samples were collected from the UK (nine), Malaysia (nine), Serbia (four) and Thailand (two), yielding 18 different formulations (10 veterinary). Packaging inspection, tablet disintegration and content assay were conducted (validated high‐performance liquid chromatography with ultra‐violet detection); content was acceptable when within the 90% to 120% pre‐specified range (US Pharmacopeia).

Results

Secondary packaging was present for 13 of 24 samples and primary packaging integrity was verified for all but one sample. Amoxicillin trihydrate/potassium clavulanate label ratio was 4:1, except for three formulations (2:1). Tablet dose strength ranged from 250 to 625 mg. All formulations contained both analytes. For amoxicillin, two of 24 samples were out of specification with 72.8% (Malaysia) and 82.3% (Thailand) of labelled content. For clavulanate, four of 24 samples were out of specification with 46.9% (Serbia), 79.0% (UK), 84.3% (Serbia) and 86.5% (Thailand) of labelled content. One formulation (Thailand) failed for both analytes. Clinical Significance Antimicrobial formulations of substandard quality have negative consequences for efficacy in patients and potentially promote antimicrobial resistance. There was evidence of substandard formulations in all countries, not only for amoxicillin but especially for clavulanate; this could compromise equitable access to acceptable quality essential veterinary medicines worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amoxicillin-Potassium Clavulanate CombinationAnti-Infective AgentsAnimalsDogsMalaysiaSerbiaThailandProspective StudiesAmoxicillinClavulanic AcidTabletsUnited KingdomAnti-Bacterial Agents

Substanzen

Amoxicillin-Potassium Clavulanate CombinationAmoxicillinClavulanic AcidTabletsAnti-Infective AgentsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Clinical Services and Sciences and Department of Comparative Biomedical Sciences, Royal Veterinary College, Hatfield, UK.
  • Department of Clinical, Pharmaceutical & Biological Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.
  • Animal Medical Centre, Kuala Lumpur, Malaysia.
  • Department for Veterinary Medicine, Faculty of Agriculture, University of Novi Sad, Novi Sad, Serbia.
  • Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand.
  • Veterinary Clinical Pharmacology and Toxicology, Advanced Veterinary Therapeutics, Newtown, NSW, 2042, Australia.

ORCID-Profile: L Pelligand, P V Steagall

Zitieren

APA

Pelligand, L., Baker, D., Sivagurunathan, A., Kovačević, Z., Suemanotham, N., Stair, J. L., Scott, M., Liu, F., Page, S. W., Guardabassi, L., Steagall, P. V., & Therapeutic Guidelines Group of the World Small Animal Veterinary Association (2023). Quality of amoxicillin/clavulanic acid oral formulations for intended veterinary use in the UK, Malaysia, Serbia and Thailand. Journal of Small Animal Practice. https://doi.org/10.1111/jsap.13648

Vancouver

Pelligand L, Baker D, Sivagurunathan A, Kovačević Z, Suemanotham N, Stair JL, et al. Quality of amoxicillin/clavulanic acid oral formulations for intended veterinary use in the UK, Malaysia, Serbia and Thailand. Journal of Small Animal Practice. 2023. doi:10.1111/jsap.13648

BibTeX
@article{Pelligand2023,
  author = {Pelligand, L and Baker, D and Sivagurunathan, A and Kovačević, Z and Suemanotham, N and Stair, J L and Scott, M and Liu, F and Page, S W and Guardabassi, L and Steagall, P V and Therapeutic Guidelines Group of the World Small Animal Veterinary Association, Therapeutic Guidelines Group of the World Small Animal Veterinary Association},
  title = {Quality of amoxicillin/clavulanic acid oral formulations for intended veterinary use in the UK, Malaysia, Serbia and Thailand},
  journal = {Journal of Small Animal Practice},
  year = {2023},
  doi = {10.1111/jsap.13648}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche